Slovakia

BMI View: Our weak 2012 outlook for Slovakia's pharmaceutical market has been maintained with the passage of key drug policy reforms in September, prior to the fall of Iveta Radicová's... 2011-10-20

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: While 2012 is set to be an unusually difficult year for drugmakers in Central Europe, we maintain our view that the long-term growth potential of this region is favourable,... 2011-08-25

BMI View: The content and process of new legislation relating to drug and healthcare reforms in Slovakia has been strongly criticised by a leading local pharmaceutical association.... 2011-07-05

BMI View: Slovakia's pharmaceutical market is set for an extended period of low growth and lower prices. The legislative progression of the drug policy reform is nearing completion,... 2011-06-24

BMI View: The promotion of generic drugs is crucial to the Slovakian government measures to reduce the costs of the publicly-funded drug reimbursement regime. However, the introduction... 2011-03-25

BMI View: Slovakia's pharmaceutical market is set for an extended period of low growth and lower prices. The government is preparing to introduce drug policy amendments in the latter... 2011-02-25